News | October 27, 2022
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
The round also saw participation from US-based fund 57 Stars, a few prominent angel investors, existing investors Stellaris Venture Partners, Vertex Ventures, and Alteria Capital
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
Subscribe To Our Newsletter & Stay Updated
